RIL
ELVN icon

Rothschild Investment LLC’s Enliven Therapeutics ELVN Stock Holding History

Rothschild Investment LLC’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08K Buy
41
+1
+3% +$42 ﹤0.01% 2746
2026
Q1 		$1.57K Buy
40
+20
+100% +$554 ﹤0.01% 2663
2025
Q4 		$308 Sell
20
-25
-56% -$498 ﹤0.01% 3040
2025
Q3 		$921 Hold
45
– – ﹤0.01% 2620
2025
Q2 		$903 Hold
45
– – ﹤0.01% 2527
2025
Q1 		$886 Buy
45
+5
+13% +$108 ﹤0.01% 2407
2024
Q4 		$900 Buy
40
+5
+14% +$130 ﹤0.01% 2273
2024
Q3 		$894 Buy
35
+30
+600% +$695 ﹤0.01% 2249
2024
Q2 		$117 Buy
+5
New +$105 ﹤0.01% 2689

Other funds holding ELVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Rothschild Investment LLC's ELVN Position: Q2 2026 in Review

Rothschild Investment LLC increased its Enliven Therapeutics (ELVN) stake by 2.5% in Q2 2026, buying an estimated $42 and bringing the position to 41 shares worth $2.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2746.

Rothschild Investment LLC first reported a position in ELVN in Q2 2024 and has held it in 9 quarters since. 49 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Rothschild Investment LLC held 41 shares of Enliven Therapeutics worth $2.08K as of Q2 2026.
  • Rothschild Investment LLC bought 1 Enliven Therapeutics share in Q2 2026, an estimated $42.
  • Enliven Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2746 holding.
  • Rothschild Investment LLC first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 49 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.